Federal contract award
HHSN272201600029C
IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541711 |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $48.5M |
| Current contract value | $48.5M |
| Potential contract value / ceiling | $48.5M |
| Start date | Sep 19, 2016 |
| Current end date | Mar 31, 2026 |
| Potential end date | Mar 31, 2026 |
| Latest award activity | Jul 31, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 31 of 31 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 31, 2026 | P00030 | $-60.7K | TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. |
| Sep 23, 2025 | P00029 | $-195.9K | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| May 22, 2025 | P00028 | $0 | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Sep 10, 2024 | P00027 | $-94.7K | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Aug 20, 2024 | P00026 | $370.3K | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Jun 28, 2024 | P00025 | $0 | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Jun 7, 2023 | P00024 | $3.3M | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Jan 6, 2023 | P00023 | $0 | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001) A BETA-LACTAM CLINICAL STUDY (CLIN 002) A NON-GLP |
| Aug 3, 2022 | P00022 | $0 | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Mar 4, 2022 | P00021 | $2.3M | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Sep 28, 2021 | P00020 | $-1 | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Sep 16, 2021 | P00019 | $4.0M | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Jun 14, 2021 | P00018 | $0 | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Mar 9, 2021 | P00017 | $439.7K | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Dec 30, 2020 | P00016 | $0 | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Sep 28, 2020 | P00015 | $0 | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Sep 3, 2020 | P00014 | $1.9M | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Apr 22, 2020 | P00013 | $1.2M | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Mar 3, 2020 | P00012 | $0 | THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP |
| Nov 20, 2019 | P00011 | $0 | ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Sep 11, 2019 | P00010 | $0 | IGF OT IGF - ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Aug 28, 2019 | P00009 | $1.4M | IGF OT IGF - ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| May 29, 2019 | P00008 | $7.2M | IGF::OT::IGF - ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Mar 27, 2019 | P00007 | $2.5M | IGF::OT::IGF - ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Jan 24, 2019 | P00006 | $0 | IGF::OT::IGF - ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Dec 12, 2018 | P00005 | $1.2M | IGF::OT::IGF - ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Sep 19, 2018 | 4 | $2.8M | IGF::OT::IGF - ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Feb 26, 2018 | 3 | $4.0M | IGF::OT::IGF - ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Sep 12, 2017 | 2 | $9.2M | IGF::OT::IGF - ORALLY BIOAVAILABLE B-LACTAM/B-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Feb 3, 2017 | 1 | $0 | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
| Sep 19, 2016 | 0 | $7.1M | IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.